A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 6440
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GLP-1
Long Form : glucagon-like peptide-1
No. Year Title Co-occurring Abbreviation
2020 (EX-4)2-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression. DIO, MAPK, NF-kappaB, T2D
2020 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). ADA, CKD, CVD, EASD, HHF, MACE, SGLT2
2020 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). ADA, CKD, CVD, EASD, HHF, MACE, SGLT2
2020 A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. BMI, OGTT
2020 A Comparison of Gastric and Jejunal Feeding in Hypercatabolism Associated With Hypothalamic AMPK-Autophagy-POMC in Endotoxemic Rats. AMPK, EN, GF, GHS-R1alpha, JF, LPS, POMC
2020 A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. AD, GCG, LTP, Oxm, T2DM
2020 A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R. GPCRs
2020 A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine. DM, GMS, HG, L group, LA, NIA, NIT, SDs
2020 A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model. GLP-2, PD, TEM
10  2020 A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? NAFLD, SGLT2, T2D
11  2020 A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. DIO, GCG, NASH, OXM, PEG
12  2020 A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain. CNS, mApple
13  2020 A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential. GIP, OGTT
14  2020 A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin. DPP4, GIP, NEP, PB
15  2020 A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery. ---
16  2020 A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance. GIP, IGT, OGTTs, RHI, T2D
17  2020 A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes. GIP
18  2020 A Review of the Renoprotective Effects of Novel Antidiabetic Agents. DPP-4, SGLT2
19  2020 A systematic review and meta-analysis of medium-chain triglycerides effects on acute satiety and food intake. GIP, LCT, MCT, PP, PYY
20  2020 Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs. AAA, DPP-4, SGLT2, SU, TZD
21  2020 Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. ---
22  2020 Activation of the GLP-1 receptor by a non-peptidic agonist. ---
23  2020 Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction. AMPK, DPP-4, SIRT1, TRPV4
24  2020 Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study. T2D
25  2020 Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes. EPCs, ET-1, NO, SDF-1alpha
26  2020 Acute exposure to a hot ambient temperature reduces energy intake but does not affect gut hormones in men during rest. PYY
27  2020 Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. DPP4, SGLT2
28  2020 Albumin-binding domain extends half-life of glucagon-like peptide-1. ABD, HSA, T2DM
29  2020 Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. AUD, Ex-4
30  2020 Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. ---
31  2020 Alterations in Enteroendocrine Hormones After Total Pancreatectomy With Islet Autotransplantation. PP, PYY, TPIAT
32  2020 Alterations in pancreatic islet cell function in response to small bowel resection. SBR
33  2020 Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice. ACC, AMPK, FSI
34  2020 Amino Acids in Health and Endocrine Function. IGF-1
35  2020 An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial. a-LCD, LCD, LFD
36  2020 An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice. OHP2
37  2020 Anagliptin stimulates osteoblastic cell differentiation and mineralization. ALP, OCN, OPN
38  2020 Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation. Ana, DPP-4, ICIs, LIG
39  2020 Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice. DIO, OXT
40  2020 Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein. DC, DPP-4, HP, Myr, NLRP3, STZ
41  2020 Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic alpha-cell transdifferentiation. GIP, SGLT2
42  2020 Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. CIs, DPP4, NAFLD, SGLT2, SMDs, WMDs
43  2020 Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice. FBG, Se-B. longum DD98, STZ
44  2020 Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. HCC, NAFLD, NASH, SGLT2, T2D
45  2020 Appetite control: hormones or diet strategies? PYY
46  2020 Appetite-regulating hormones and anthropometric indicators of infants according to the type of feeding. FBF, HMS, PBF
47  2020 Appetite-Regulating Hormones in Human Milk: A Plausible Biological Factor for Obesity Risk Reduction? PYY
48  2020 Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced. ---
49  2020 Assessing the effect of starch digestion characteristics on ileal brake activation in broiler chickens. PYY, SCFA, WS
50  2020 Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. HRs, SGLT2
51  2020 Assessment of antidiabetic potential and phytochemical profiling of Rhazya stricta root extracts. DPP-IV
52  2020 Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015. DPP-4, SGLT2
53  2020 Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. GE, SNPs
54  2020 Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. DPP-4, GLP-1R
55  2020 Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. CA7S, GI, TGR5
56  2020 Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress. ---
57  2020 Bifidobacterium from breastfed infant faeces prevent high-fat-diet-induced glucose tolerance impairment, mediated by the modulation of glucose intake and the incretin hormone secretion axis. HFD
58  2020 Bile acid treatment and FXR agonism lower postprandial lipemia in mice. DCA, FXR, TA, TGR5
59  2020 Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius. NTS, PPG
60  2020 Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process. ---
61  2020 Brain insulin resistance: role in neurodegenerative disease and potential for targeting. GIP
62  2020 Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. AD, BBB, CNS, GIP, IRAs, PD
63  2020 Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota. PYY
64  2020 Cacao polyphenols regulate the circadian clock gene expression and through glucagon-like peptide-1 secretion. CLPr
65  2020 Caloric restriction alters the hormonal profile and testicular metabolome, resulting in alterations of sperm head morphology. CR
66  2020 Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality? ---
67  2020 Capsaicin improves glucose homeostasis by enhancing glucagon-like peptide-1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice. BA, CAP, HFD, LCA, TGR5
68  2020 Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-alpha. caECs, CASMCs, MTPalpha, NEP-generated, sAC-dependent
69  2020 Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. CKD, SGLT2, T2D
70  2020 Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. GLP-1RAs, T2DM
71  2020 CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon. CCK, GIP, PYY, VIP
72  2020 Cerebral effects of GLP-1 receptor blockade before and after Roux-en-Y Gastric Bypass in obese women: a proof-of-concept resting-state fMRI study. RYGB
73  2020 Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication. ATC, DPP-4, OR, SGLT2
74  2020 Childhood trauma and glucose metabolism in patients with first-episode psychosis. BMI, CT, FEP, GIP, PAI-1, SLEs
75  2020 Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora. COS, CYP7A1, HMGCR, SMYD3, T2DM
76  2020 Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. JVC, TPN
77  2020 Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents. Ex-4, HFF, LFF, NTS
78  2020 Chronic n-3 fatty acid intake enhances insulin response to oral glucose and elevates GLP-1 in high-fat diet-fed obese mice. cHF, OGTT, PUFA
79  2020 Circadian GLP-1 Secretion in Mice is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis. ---
80  2020 Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. UKELD
81  2020 Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. AGEs, BMI, i.v, OGTT, sRAGE
82  2020 Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. GIP, PYY, T2D
83  2020 Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice. DIO
84  2020 Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. CV, SGLT2
85  2020 Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? CKD, NAFLD, NASH, SGLT2, SKLT, T2D
86  2020 Comparable Postprandial Amino Acid and Gastrointestinal Hormone Responses to Beef Steak Cooked Using Different Methods: A Randomised Crossover Trial. aa, GI, GIP, PF, SV, UPLC
87  2020 Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data. ---
88  2020 Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis. alpha-GIs, DPP-4, HOMA-beta, PIR, SGLT2
89  2020 Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats. Ang II
90  2020 Consuming decaffeinated coffee with milk and sugar added before a high-glycaemic index meal improves postprandial glycaemic and insulinaemic responses in healthy adults. GI
91  2020 Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier. MOFs
92  2020 Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. AEs, BMI, NHS, QALYs, SA, T2DM, UKPDS
93  2020 Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. ACEI, ARBs, NSAIDs, SYRCLE
94  2020 Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids. CCPP, PYY, SCFAs, T2DM
95  2020 Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. SGLT2
96  2020 Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE. ---
97  2020 Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. CI, DPP4, IRR
98  2020 Diabetes: From Research to Clinical Practice. CGM, CSII, SGLT2
99  2020 Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21. ABs, Cy3G, Exp, FGF21, HFD, LFD
100  2020 Dietary macronutrient regulation of acyl and desacyl ghrelin concentrations in children with Prader-Willi syndrome (PWS). AG, DAG, HC, HP-LC, HP-LF, PWS, PYY